Search clinical trials for: IC31® Adjuvant

Total 21628 results

Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
Statens Serum Institut

Completed

A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers (THYB-02)

Tuberculosis

Netherlands
Aeras
Oslo University Hospital; University of Copenhagen; University of Bergen; Aurum... and other collaborators

Withdrawn

A Phase II Study of H56:IC31 in Healthy Adolescents (A-043)

Tuberculosis Infection

South Africa, Tanzania
Aeras
Sanofi Pasteur, a Sanofi Company; Statens Serum Institut; HIV Vaccine Trials...

Completed

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

Tuberculosis

South Africa
Statens Serum Institut

Completed

A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) (THYB-03)

Tuberculosis
Aeras
Statens Serum Institut

Completed

A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB (C-037-456)

Tuberculosis

South Africa
International AIDS Vaccine Initiative
University of Cape Town Lung Institute; European and Developing Countries Clinical... and other collaborators

Active, not recruiting

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Tuberculosis, Pulmonary

South Africa, Tanzania
Aeras
Statens Serum Institut

Completed

Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis

Latent Tuberculosis | Latent Tuberculosis Bacteriology and Histology Unknown

South Africa
Affiris AG
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Completed

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA (AFF009)

Neurodegenerative Diseases | Multiple System Atrophy

France
Affiris AG
Medical University of Vienna

Completed

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (AFF012)

Hypercholesterolemia

Austria
Affiris AG
Medical University Innsbruck; Forschungszentrum Juelich; PROSENEX AmbulatoriumbetriebsGMBH

Completed

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease (AFF011)

Parkinson Disease | Neurodegenerative Diseases

Austria
Tang-Du Hospital

Recruiting

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Carcinoma, Non-Small-Cell Lung | Neoplasm, Residual | Circulating Tumor DNA | Next-Generation Sequencing | Chemotherapy, Adjuvant

China
Molecular Insight Pharmaceuticals, Inc.

Unknown

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Valneva Austria GmbH

Completed

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

Japanese Encephalitis

Australia, United States, Germany
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Tuberculosis

South Africa
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
Valneva Austria GmbH

Completed

Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

Chronic Hepatitis C
Affiris AG
University Hospital Tuebingen

Withdrawn

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

Parkinson's Disease

Germany
Valneva Austria GmbH

Completed

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis

Austria, Germany
Valneva Austria GmbH

Completed

Virological Response Study of the HCV Vaccine IC41

Chronic Hepatitis C

Germany, Poland, Romania
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? (ESTIMABL2)

Low Risk Differentiated Thyroid Cancer

France
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Agenus Inc.

Completed

Phase 1a Study to Evaluate Immunogenicity of ASV®

Solid Tumor, Adult

United States
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults (C-013-404)

Tuberculosis

Switzerland
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
Dynavax Technologies Corporation
United States Department of Defense

Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
Hangzhou Converd Co., Ltd.
The Second Hospital of Jia Xing

Unknown

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer

Gastrointestinal Cancer
Hangzhou Converd Co., Ltd.
The Second People's Hospital of Yibin

Unknown

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors

Advanced Solid Tumors
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
AC Camargo Cancer Center

Withdrawn

Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors (MIBNET)

Neuroendocrine Tumors

Brazil
Hospital Juarez de Mexico

Completed

Effect of I31 Probiotic on Lactose Intolerance

Lactose Intolerance

Mexico
National Institute of Allergy and Infectious Diseases...
PepTcell Limited (t/a SEEK)

Completed

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Mosquito-Borne Infectious Diseases

United States
Statens Serum Institut
Bill and Melinda Gates Foundation; Aurum Institute; Leiden University Medical... and other collaborators

Recruiting

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b (nTB-01)

Healthy

South Africa
Masonic Cancer Center, University of Minnesota

Terminated

Vaccination With Tetanus and KLH to Assess Immune Responses.

Cancer

United States
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Epimmune

Unknown

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Tumors

United States
Oryx GmbH & Co. KG

Completed

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)

HPV-induced Cancers

Germany
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Terminated

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Autoimmune Disorders

United States
University of Maryland, Baltimore
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Prostate Cancer
Hospices Civils de Lyon

Recruiting

Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy (TOXSIALO)

Cerebral Palsy

France
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Kenya...

Completed

A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants

Malaria,Falciparum

Kenya
Region Skane

Completed

Cerebral Changes Following CTS Treated With Guided Plasticity

Carpal Tunnel Syndrome
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea (CJCV1-01)

Campylobacter Infection

United States
Colby Pharmaceutical Company

Completed

Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects

Influenza

3

Subscribe